Product
Recombinant Human Tissue Plasminogen Kinase
1 clinical trial
1 indication
Indication
StrokeClinical trial
A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic StrokeStatus: Completed, Estimated PCD: 2023-06-22